Literature DB >> 3458518

Comparison of mitoxantrone and ametantrone in human acute myelocytic leukemia cells in culture and in bone marrow granulocyte-macrophage progenitor cells.

G Fountzilas, T Ohnuma, K Rammos, B Mindich, J F Holland.   

Abstract

The cytocidal effects of mitoxantrone and ametantrone were compared in 3 human acute myelocytic leukemia (AML) cell lines by means of clonogenic as well as cell growth inhibition assay. The effects of these two agents were also compared on normal bone marrow granulocyte-macrophage progenitor cells (CFU-GM). Mitoxantrone was 10-20 fold more potent against AML cells than ametantrone. Longer exposure of cells to these agents resulted in increased cell kill, but with lesser efficiency. Both mitoxantrone and ametantrone were more cytocidal on normal bone marrow CFU-GM than on AML cells; mitoxantrone was approximately 2.5-fold and ametantrone nearly 10-fold more active against CFU-GM than against HL-60 AML cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3458518     DOI: 10.1089/cdd.1986.3.93

Source DB:  PubMed          Journal:  Cancer Drug Deliv        ISSN: 0732-9482


  3 in total

Review 1.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

2.  High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule.

Authors:  A Ballestrero; F Ferrando; A Garuti; P Basta; R Gonella; M Esposito; M O Vannozzi; G Sorice; D Friedman; M Puglisi; F Brema; G S Mela; M Sessarego; F Patrone
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  B Richard; M C Launay-Iliadis; A Iliadis; S Just-Landi; D Blaise; A M Stoppa; P Viens; M H Gaspard; D Maraninchi; J P Cano
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.